Cladribine, Low-Dose Cytarabine (LDAC), and Venetoclax (VEN) in Older/Unfit Acute Myeloid Leukemia (AML) Patients: A Single-Institution Experience

被引：0
|
作者：
Yohannan, Binoy [1 ]
Khan, Hina [1 ]
Cervoni-Curet, Frances [1 ]
Rios, Adan [1 ]
机构：
[1] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Houston, TX 77030 USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
AML; cladribine; low-dose cytarabine; older/unfit AML;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
AML-100
引用
收藏
页码：S267 / S267
页数：1
相关论文
共 50 条
  • [21] Clinical Outcomes of Nucleophosmin (NPM1) Mutant Acute Myeloid Leukemia (AML): A Single-Institution Experience
    Yohannan, Binoy
    Chan, Kok Hoe
    Cervonicuret, Frances
    Rios, Adan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S283 - S283
  • [22] TREATMENT OF ACUTE MYELOID-LEUKEMIA IN THE ELDERLY WITH LOW-DOSE CYTARABINE, HYDROXYUREA, AND CALCITRIOL
    SLAPAK, CA
    DESFORGES, JF
    FOGAREN, T
    MILLER, KB
    AMERICAN JOURNAL OF HEMATOLOGY, 1992, 41 (03) : 178 - 183
  • [23] A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia
    Bazinet, Alexandre
    Darbaniyan, Faezeh
    Kadia, Tapan M.
    Venugopal, Sangeetha
    Kanagal-Shamanna, Rashmi
    DiNardo, Courtney D.
    Borthakur, Gautam
    Jabbour, Elias J.
    Daver, Naval G.
    Pemmaraju, Naveen
    Konopleva, Marina Y.
    Ravandi, Farhad
    Sasaki, Koji
    Chien, Kelly S.
    Hammond, Danielle
    Pierce, Sherry A.
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    Montalban-Bravo, Guillermo
    CANCER, 2023, 129 (04) : 560 - 568
  • [24] Venetoclax combination therapy in relapsed/refractory acute myeloid leukemia: A single institution experience
    Gaut, Daria
    Burkenroad, Aaron
    Duong, Tuyen
    Feammelli, Jesse
    Sasine, Joshua
    Schiller, Gary
    LEUKEMIA RESEARCH, 2020, 90
  • [25] Venetoclax plus low-dose cytarabine in patients with newly diagnosed acute myeloid leukemia ineligible for intensive chemotherapy: an expanded access study in Japan
    Asada, Noboru
    Ando, Jun
    Takada, Satoru
    Yoshida, Chikashi
    Usuki, Kensuke
    Shinagawa, Atsushi
    Ishizawa, Kenichi
    Miyamoto, Toshihiro
    Iida, Hiroatsu
    Dobashi, Nobuaki
    Okubo, Sumiko
    Honda, Hideyuki
    Soshin, Tomomi
    Nishimura, Yasuko
    Tsutsui, Atsuko
    Mukai, Harumi
    Yamamoto, Kazuhito
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2023, 53 (07) : 595 - 603
  • [26] Predictive and Prognostic Markers in Adults With Acute Myeloid Leukemia: A Single-Institution Experience
    Gbadamosi, Bolanle
    Ezekwudo, Daniel
    Bastola, Sanjog
    Jaiyesimi, Ishmael
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (07) : E287 - E294
  • [27] Venetoclax and low-dose cytarabine induced complete remission in a patient with high-risk acute myeloid leukemia: a case report
    Liu, Bingshan
    Narurkar, Roshni
    Hanmantgad, Madhura
    Zafar, Wahib
    Song, Yongping
    Liu, Delong
    FRONTIERS OF MEDICINE, 2018, 12 (05) : 593 - 599
  • [28] Combined low-dose cytarabine, melphalan and mitoxantone for older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome
    Yamauchi, Takahiro
    Negoro, Eiju
    Arai, Hajime
    Ikegaya, Satoshi
    Takagi, Kazutaka
    Takemura, Haruyuki
    Inai, Kunihiro
    Yoshida, Akira
    Urasaki, Yoshimasa
    Iwasaki, Hiromichi
    Ueda, Takanori
    ANTICANCER RESEARCH, 2007, 27 (4C) : 2635 - 2639
  • [29] Venetoclax and low-dose cytarabine induced complete remission in a patient with high-risk acute myeloid leukemia: a case report
    Bingshan Liu
    Roshni Narurkar
    Madhura Hanmantgad
    Wahib Zafar
    Yongping Song
    Delong Liu
    Frontiers of Medicine, 2018, 12 : 593 - 599
  • [30] Venetoclax in Combination With Low-Dose Cytarabine and/or Actinomycin D in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) Patients With IDH1 or IDH2 Mutations
    Daukelaite, Guoda
    Vasilevska, Dominika
    Vaitekenaite, Vilmante
    Trociukas, Igoris
    Pileckyte, Regina
    Griskevicius, Laimonas
    Zucenka, Andrius
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S293 - S294
12345